AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Ultomiris (ravulizumab) — US product sales by Year
Ultomiris (ravulizumab) — US product sales ($M) ($M)
AstraZeneca Ultomiris (ravulizumab) — US product sales: $2,667M in FY2025, up 18.0% from a year earlier.
Where the FY2025 figure comes from
“|| Ultomiris | 4,718 | 20 | 19 | 2,667 | 18 | 261 | 84 | 90 | 1,053 | 19 | 15 | 737 | 16 | 15”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ultomiris (ravulizumab) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,667 | +18.0% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 2,261 | +29.2% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 1,750 | +54.0% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 1,136 | +198.2% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 381 | – | Form 6-K FY2021Q4 Earnings Release ↗ |
Breakdown
What makes up ultomiris (ravulizumab) — US product sales
Cite this data
StockData. (2026). AstraZeneca Ultomiris (ravulizumab) — US product sales ($M), annual FY2021–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-ultomiris-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.